Ani Pharmaceuticals (ANIP) Net Cash Flow (2010 - 2026)

Ani Pharmaceuticals has disclosed Net Cash Flow across 17 years of filings, most recently posting $25.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $25.4 million, up 385.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $161.2 million (up 306.63% YoY), and the FY2025 annual result was $141.0 million, up 286.07% from the prior year.
• Net Cash Flow came in at $25.4 million for Q1 2026 at Ani Pharmaceuticals, up from $24.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $94.0 million in Q2 2023 to a low of -$95.0 million in Q3 2024.
• The 5-year median for Net Cash Flow is $11.5 million (2024), against an average of $12.1 million.
• Across the five-year window, Net Cash Flow plunged 1567.69% in 2022 and soared 8844.12% in 2025, its largest moves.
• Ani Pharmaceuticals' Net Cash Flow stood at -$8.0 million in 2022, then surged by 448.36% to $28.0 million in 2023, then plunged by 99.03% to $272000.0 in 2024, then jumped by 8844.12% to $24.3 million in 2025, then gained by 4.55% to $25.4 million in 2026.
• The last three Net Cash Flow figures came in at $25.4 million (Q1 2026), $24.3 million (Q4 2025), and $44.2 million (Q3 2025), per Business Quant data.